Related Experiment Video

Updated: Jun 17, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Targeting the transforming growth factor-beta signaling pathway in human cancer

Nagathihalli S Nagaraj1, Pran K Datta

  • 1Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, Department of Surgery, Nashville, TN 37232, USA.

Expert Opinion on Investigational Drugs
|December 17, 2009
PubMed

Insights

Transforming growth factor-beta (TGF-beta) signaling shifts from tumor suppression to promotion in advanced cancers. Inhibitors targeting TGF-beta pathways show promise for cancer treatment by blocking tumor progression.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Cell Signaling

Background:

  • The transforming growth factor-beta (TGF-beta) signaling pathway has a dual role in cancer, acting as a tumor suppressor in early stages and a tumor promoter in advanced cancers.
  • Smad-dependent pathways are linked to TGF-beta's tumor-suppressive functions, while Smad-independent pathways and loss of suppression contribute to its pro-oncogenic roles.
  • TGF-beta signaling is a recognized therapeutic target due to its involvement in tumor progression and invasion.

Purpose of the Study:

  • To elucidate the mechanisms of TGF-beta signaling in cancer progression.
  • To identify specific TGF-beta pathway targets critical for tumor invasion.
  • To review therapeutic interventions for TGF-beta signaling in human cancers.

Main Methods:

  • Review of existing literature on TGF-beta signaling mechanisms.
  • Analysis of Smad-dependent and Smad-independent pathways in cancer.
  • Examination of preclinical and clinical studies of TGF-beta pathway inhibitors.

Main Results:

  • TGF-beta's function changes from tumor suppression to promotion during cancer development.
  • Smad-independent pathways are implicated in TGF-beta's oncogenic functions in advanced cancers.
  • TGF-beta pathway inhibitors have demonstrated preclinical efficacy in various tumor models and are advancing in clinical trials.

Conclusions:

  • Targeting TGF-beta signaling presents a promising therapeutic strategy for specific cancer patient groups.
  • Identifying patients refractory to TGF-beta suppression but responsive to its promotion is key for effective treatment.
  • Further research into TGF-beta signaling mechanisms and targeted inhibitors is crucial for advancing cancer therapy.

More Related Videos

Spheroid Assay to Measure TGF-β-induced Invasion09:18

Spheroid Assay to Measure TGF-β-induced Invasion

Published on: November 16, 2011

Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System11:06

Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System

Published on: July 30, 2018

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...